- Free from Publisher D Manzella, R Grella, AM Abbatecola, G … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Sixteen type 2 diabetic patients undergoing diet
treatment and with poor glucose control volunteered for the study. The study was
designed as a 4-month, randomized, cross-over, parallel-group trial of ... Cited by 28 - Related articles - All 6 versions
[CITATION] STOP-NIDDM Trial Research Group. Effect of acarbose treatment on the risk of silent …
MR Rizzo, M Barbieri, R Grella, N Passariello … - Diabetes and Metabolism, 2005 - Elsevier Aim our study is to compare the effects of repaglinide vs glimepiride
administration on cardiovascular risk factors after meal test. Thus, after 2
weeks washout period, a 3-month randomised, cross-over parallel group trial ... Cited by 14 - Related articles - All 3 versions
T Tankova, D Koev, L Dakovska, G Kirilov - Diabetes research and clinical practice, 2003 - Elsevier The effect of repaglinide on insulin secretion and oxidative stress was
evaluated in type 2 diabetic patients in a randomized, controlled, open-label
trial. Forty-six patients were treated for 2 months with repaglinide, added ... Cited by 32 - Related articles - All 10 versions
G Derosa, A Mugellini, L Ciccarelli, G … - Diabetes research and clinical practice, 2003 - Elsevier Content-length: 1367. ... Cited by 11 - Related articles - All 8 versions
FM Bengel, C Abletshauser, J Neverve, O … - Diabetic medicine, 2005 - pt.wkhealth.com Results: MBF at rest and during adenosine did not change during the study. The
percentage of flow increase from rest during cold pressor test did not improve
significantly in the nateglinide group vs. placebo (from 26.1 ± 37.2% to ... Cited by 10 - Related articles - All 6 versions
R Assaloni, R Ros, L Quagliaro, L Piconi, A … - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 1919–1924 DOI 10.1007/s00125-005-1849-5 ARTICLE
R. Assaloni . R. Da Ros . L. Quagliaro . L. Piconi . A. Maier . G. Zuodar . ... Cited by 24 - Related articles - BL Direct - All 3 versions
G Derosa, A Mugellini, L Ciccarelli, G … - Clinical therapeutics, 2003 - Elsevier Methods: This randomized, placebo-controlled, double-blind trial was conducted
at a single center in Italy. Eligible patients were nonsmokers; had no
hypertension or coronary heart disease; were taking no hypolipidemic drugs, ... Cited by 51 - Related articles - All 5 versions
BM Balletshofer, S Goebbel, K Rittig, M … - Experimental and clinical endocrinology & diabetes: …, 2005 - ncbi.nlm.nih.gov Disturbances in nitric oxide (NO) metabolism resulting in endothelial
dysfunction play a central role in the pathogenesis of atherosclerosis in
hypercholesterolemia and in individuals with type 2 diabetes. It is unclear ... Cited by 12 - Related articles - All 3 versions
K Mizushige, T Tsuji, T Noma - Cardiovascular drug reviews, 2002 - interscience.wiley.com Pioglitazone is the second thiazolidine derivative used clinically in the type 2
diabetes mellitus (DM). In the prediabetic stage, hyperinsulinemia or insulin
resistance has been suggested to be closely associated with the oxidative ... Cited by 13 - Related articles - BL Direct - All 5 versions
